FDA and ONC Compliance Testing Strategy

The Real Buyer Problem: Shipping Product Without Triggering a Regulatory Train Wreck

If you are a Series B digital health CEO or a CTO at a health IT vendor, you already feel it: every release is a trade-off between velocity and regulatory exposure. A missed traceability link, incomplete validation report, or poorly documented change control can stall a hospital deployment—or worse, trigger corrective action during an FDA inspection.

For teams building Software as a Medical Device (SaMD) or certified health IT modules, the question is not “do we test?” It’s “can we prove, with evidence, that we tested the right things, at the right depth, and under a compliant quality system?”

When our team at AST stepped into a rebuild of a clinical decision support platform preparing for FDA review, the biggest issue was not code quality. It was fragmented evidence—requirements in one system, test cases in another, and no defensible link between risk controls and verification artifacts. That is where most compliance failures live.

Core Regulatory Anchors You Must Design Testing Around

Before talking about tools or frameworks, anchor on the standards that drive your testing posture:

• 21 CFR Part 820 — Quality System Regulation (design controls, CAPA, complaint handling).
• 21 CFR Part 11 — Electronic records and signatures.
• 45 CFR Part 170 — ONC Health IT Certification criteria.
• ISO 13485 and IEC 62304 — often expected for SaMD lifecycle rigor.

Your testing strategy must explicitly map to these. If it does not, you are relying on hope.

Four Testing Architectures for FDA & ONC Compliance

Not all testing strategies are equal. We typically see four patterns in the market.

1. Risk-Based Test Architecture

This is the backbone for regulated teams. Start with formal hazard analysis and risk assessment. Each identified risk must map to mitigation controls and then to explicit verification tests. Your test management system should enforce many-to-many linkage.

At AST, our Quality & Testing pods build traceability matrices directly into the delivery pipeline. When a developer commits code tied to a requirement, it references a requirement ID, which connects to a risk control entry and corresponding automated and manual test suites. Evidence generation is automated wherever possible.

2. Validated CI/CD Pipelines

Speed is not the enemy of compliance. Uncontrolled change is. For FDA-regulated products, your CI/CD pipeline itself may need validation. That means documented configuration, access controls, version control policies, and electronic signature controls aligned to 21 CFR Part 11.

In practice, that includes:

• Role-based access and immutable audit logs.
• Automated test execution with timestamped results.
• Release gating based on documented approval workflows.

We have implemented this pattern for clinical platforms serving over 160 respiratory care facilities. The key lesson: automate test execution, but formalize release authorization. Engineers build; quality signs off within a controlled workflow.

3. Structured System Validation (IQ/OQ/PQ Mindset)

Borrow from validated system approaches common in life sciences: Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ). Even if not formally required, this structure strengthens ONC and FDA readiness.

• IQ: Verify environment configuration and infrastructure controls.
• OQ: Validate functionality against system requirements.
• PQ: Demonstrate real-world performance and clinical workflow alignment.

For ONC certification modules, we explicitly script test scenarios to mirror certification test procedures under 45 CFR Part 170. That reduces surprises during authorized testing body (ATB) review.

4. Independent Verification & Validation (IV&V)

For higher-risk software classifications, separation of duties matters. An independent QA team validates against requirements without being influenced by delivery pressure.

AST’s pod model supports this by allocating QA leadership who reports within the pod but maintains quality authority. In several SaMD engagements, that structural separation prevented premature release when risk mitigations were incomplete.

AST’s Testing Model for Regulated Health Tech

We are not a staff augmentation shop that drops a tester into your sprint ceremony. Our pods own quality end-to-end. That means:

• Requirements clarity workshops before development begins.
• Risk modeling sessions tied to product features.
• Automated + manual test design aligned to regulatory controls.
• Audit rehearsal and mock inspection support.

Across eight years in US healthcare IT, we have seen one constant: teams who bolt compliance on at the end always pay more—either in remediation, delayed revenue, or lost credibility with enterprise buyers.

A Practical Decision Framework

1. Classify Your Product Risk Determine whether you fall under SaMD, ONC certification, or both. Regulatory scope defines testing depth.
2. Map Requirements to Risk Controls Build a living traceability matrix before writing large volumes of code.
3. Design Validation into CI/CD Ensure pipelines generate controlled, reviewable artifacts.
4. Rehearse the Audit Conduct an internal mock inspection. If you cannot produce requested evidence within 30–60 minutes, tighten your process.

FAQ